A MediCom Oncology Site
Create an account
Clinical Advisory Board
Clinical Case Snapshots
Clinical Pearls Podcasts
Journal Club Library
Clinical Expert Commentaries
2018 RRMM Symposium Replay
Criteria for Diagnosis
Revised International Staging System for Multiple Myeloma
Annual Meeting Highlights
Accredited E-Newsletter Series
Challenging Cases in RRMM Symposium Replay
Comorbid Patients with Multiple Myeloma: Considering All the Facts in Treatment Selection
--- Archives ---
RRMM Navigating New Treatment Paradigms
Clinical Dialogues™ in Multiple Myeloma
Clinical Discussion Series
Recognizing the Signs and Symptoms of MM in the Primary Care Setting
CE for Nurses
FAQ Library - Emerging Therapeutics
What is the CyBorD regimen's safety and efficacy as a primary therapy?
Robert Z. Orlowski, MD, PhD
May 9, 2013
Dr. Robert Orlowski explains the CyBorD regimen and its safety and efficacy as an induction therapy.
Are multi-agent therapies more effective than single and double therapies?
George Somlo, MD, FACP
January 24, 2012
Dr. Somlo discusses the effectiveness of multi-agents therapies versus the single, double, and triple therapies.
Results 1 - 2 of 2
MediCom Worldwide, Inc. Links